Baseline predictors included cognitive performance, <i>APOE4</i> status, plasma phosphorylated tau (p-tau) 217, "AD-signature" cortical thickness, hippocampal volume, and white matter hyperintensities (WMHs) measured by the Fazekas scale. This evidence concerns the gene MAPT and Alzheimer disease.